Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Events
  5. Conferences

Conferences

Thumbnail
June 17, 2022

The mystery of Jemperli’s rectal cancer breakthrough

If Jemperli might effectively cure a biomarker-defined subset of rectal cancer patients why isn't pharma more interested?

Thumbnail
June 14, 2022

Endo 2022 – Voxzogo’s prospects shrink

Article image
Vantage logo
June 06, 2022

Asco 2022 weekend story roundup

Article image
Vantage logo
June 06, 2022

Asco 2022 – Adicet works hard to avoid the allo Car-T scenario

Long-awaited gamma-delta Car-T data sees the response rate fall to 20% at six months, but when is a relapse not a relapse?

Article image
Vantage logo
June 06, 2022

Asco 2022 – the spirit of Rova-T struggles to live on

DLL3, a pariah antigen after the implosion of Abbvie’s Rova-T, holds the interest of a handful of industry players.

Article image
Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Another strong readout could redefine how Her2-negative breast cancer is treated, though a declared victory in triple-negatives is less clear.

Article image
Vantage logo
June 05, 2022

Asco 2022 – investors clutch at the Tigit straws

Roche’s SCLC study is an unmitigated disaster, but investors holding out for success in NSCLC are thrown a crumb of comfort.

Article image
Vantage logo
June 05, 2022

Asco 2022 – Carvykti casts a long shadow

Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.

Article image
Vantage logo
June 05, 2022

Asco 2022 – Merus gets some competition

Response rates with zenocutuzumab hold up, but Elevation Oncology’s rival project looks similar.

Article image
Vantage logo
June 04, 2022

Asco 2022 – Merck’s follow-on immuno-oncology plan hits a myositis problem

ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.

Article image
Vantage logo
June 04, 2022

Asco 2022 – Abbvie goes back to basics with navitoclax

Abbvie’s decades-old work into Bcl-2 inhibition gave rise to Venclexta, but the group has gone back to studying a Venclexta predecessor compound.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.